{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:38:39Z","timestamp":1765262319371,"version":"3.46.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ipilimumab-induced nephritis is a rare but potentially severe immune-related adverse event with incompletely defined clinical features and outcomes. This study aimed to synthesize its clinical presentation, pathology, management, and prognosis to facilitate timely recognition and evidence-based care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified cases of ipilimumab-induced nephritis from 28 published articles up to May 31, 2025, and abstracted individual patient-level data for descriptive analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 30 patients were included (26 male, 4 female; median age 63\u202fyears [range: 43, 78]). The median onset of nephritis following ipilimumab initiation was 7\u202fweeks (range: 1, 48\u202fweeks). Clinically, patients commonly presented with fatigue (26.7%), fever (20.0%), rash (13.3%), and weight loss (13.3%). Laboratory findings included elevated serum creatinine (median 3.4\u202fmg\/dL, range: 1.6, 10.4), eosinophilia (18.5%), proteinuria (14.8%), urinary tract infection (11.1%), increased C-reactive protein (7.4%), and neutrophilic leukocytosis (3.7%). Histopathological analysis revealed acute tubulointerstitial nephritis in 87.5% of cases, followed by IgA nephropathy (12.5%), and interstitial edema (4.2%). The cornerstone of treatment was immediate discontinuation of ipilimumab, coupled with systemic corticosteroids. In select cases, immunosuppressive agents (e.g., mycophenolate mofetil, infliximab, cyclophosphamide) or renal replacement therapies (hemodialysis, plasma exchange) were utilized, though their efficacy requires further validation. Clinical improvement was observed in 93.3% of patients, with a median recovery time of 7\u202fweeks (range: 1, 36\u202fweeks), while 3.3% experienced fatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings underscore the importance of early recognition and prompt intervention. A thorough clinical evaluation, including symptom assessment, physical examination, and laboratory testing, is essential for accurate diagnosis. Corticosteroids remain the mainstay of therapy, and early drug withdrawal is critical in mitigating renal injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1693359","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:11Z","timestamp":1765261751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, management, and prognostic outcomes of ipilimumab-induced nephritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhenglin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with Nivolumab plus Ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (Iraes) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in microsatellite-instability-high metastatic colorectal Cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to Ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Investig New Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12882-019-1552-2","article-title":"Ipilimumab-induced renal granulomatous arteritis: a case report","volume":"20","author":"Lemoine","year":"2019","journal-title":"BMC Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-017-0261-2","article-title":"Acute interstitial nephritis after sequential Ipilumumab - Nivolumab therapy of metastatic melanoma","volume":"5","author":"Bottlaender","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to Pd-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.kint.2018.11.009","article-title":"Interstitial nephritis in immune checkpoint inhibitor therapy","volume":"96","author":"Manohar","year":"2019","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40425-019-0655-4","article-title":"Response to combined Ipilimumab and Nivolumab after development of a nephrotic syndrome related to Pd-1 monotherapy","volume":"7","author":"Glutsch","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with Cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis with programmed cell death 1 inhibitor therapy in lung Cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13256-021-02766-w","article-title":"Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report","volume":"15","author":"Kyriazis","year":"2021","journal-title":"J Med Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000517502","article-title":"Development of Nivolumab\/Ipilimumab-associated autoimmune nephritis during steroid therapy","volume":"11","author":"Gebauer","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100626","DOI":"10.1016\/j.xkme.2023.100626","article-title":"Immune checkpoint inhibitor-associated sarcoidosis reaction in the kidney: case report","volume":"5","author":"Charkviani","year":"2023","journal-title":"Kidney Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-023-03091-8","article-title":"Immune checkpoint inhibitors associated granulomatous small vessel Vasculitis accompanied with Tubulointerstitial nephritis: a case report","volume":"24","author":"Tominaga","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.46883\/ONC.2020.3405.0171","article-title":"Immune-related adverse events involving multiple organ sites in a patient treated with Nivolumab plus Ipilimumab","volume":"34","author":"Remolina-Bonilla","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e001198","DOI":"10.1136\/jitc-2020-001198","article-title":"Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma","volume":"8","author":"Patel","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e15358","DOI":"10.7759\/cureus.15358","article-title":"Immunotherapy-induced acute Tubulointerstitial nephritis","volume":"13","author":"Parza","year":"2021","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/cji.0000000000000296","article-title":"Severe acute kidney injury due to Nivolumab\/Ipilimumab-induced granulomatosis and Fibrinoid vascular necrosis","volume":"43","author":"Person","year":"2020","journal-title":"J Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/cmr.0000000000000928","article-title":"Small-vessel Vasculitis leading to severe acute kidney injury after Ipilimumab: a case report","volume":"34","author":"Duarte","year":"2024","journal-title":"Melanoma Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s13730-024-00855-5","article-title":"Two acute kidney injury episodes after Ici therapy: a case report","volume":"13","author":"Ishiga","year":"2024","journal-title":"CEN Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"993622","DOI":"10.3389\/fimmu.2022.993622","article-title":"Nivolumab plus Ipilimumab induced Endocrinopathy and acute interstitial nephritis in metastatic Sarcomatoid renal-cell carcinoma: a case report and review of literature","volume":"13","author":"Hino","year":"2022","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-Ctla4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e41781","DOI":"10.7759\/cureus.41781","article-title":"Multiorgan failure from Nivolumab and Ipilimumab: a case report and literature review","volume":"15","author":"Brazel","year":"2023","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s13691-022-00561-y","article-title":"Two case reports of immune checkpoint therapy on Chromophobe renal cell carcinoma with Sarcomatoid differentiation","volume":"11","author":"Fukushima","year":"2022","journal-title":"Int Cancer Conf J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13256-021-03097-6","article-title":"Myocarditis as an immune-related adverse event following treatment with Ipilimumab and Nivolumab combination therapy for metastatic renal cell carcinoma: a case report","volume":"15","author":"Miyauchi","year":"2021","journal-title":"J Med Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12882-024-03494-1","article-title":"Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature","volume":"25","author":"Saiki","year":"2024","journal-title":"BMC Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5980\/jpnjurol.112.109","article-title":"Interstitial nephritis caused by Ipilimumab and Nivolumab combination therapy for advanced renal cell carcinoma: a case report","volume":"112","author":"Ishii","year":"2021","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus Ipilimumab versus Sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase iii checkmate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1353339","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Nephrotoxicity: a position statement from the American Society of Onco-Nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (Icis); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1693359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:29:11Z","timestamp":1765261751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1693359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"alternative-id":["10.3389\/fmed.2025.1693359"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1693359","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1693359"}}